SEP 25, 2020 7:00 AM PDT

Ray of Hope: Rare Cancer Biomarker Discovered

WRITTEN BY: Tara Fernandez

Biliary tract cancer, or BTC, isn’t as talked about as breast or prostate cancers, probably because its incidence is much rarer. BTCs are a group of gastrointestinal tumors including gallbladder cancers whose prevalence is increasing in South America and Asia. In Western countries, only around 1.6 in every 100,000 get diagnosed with the disease, but when they do, the mortality rate is staggeringly high: most patients die within 1 year of starting chemo.

A team of Danish researchers has identified a silver lining for BTC patients — a biomarker that can serve as a barometer for how aggressive the cancer is.

Speaking on the significance of the discovery, Jesper Andersen, one of the scientists leading the study said: "We have found a biomarker that reliably predicts how aggressively a patient’s disease will evolve, which in the future could help doctors in the hospitals make the right decisions about chemotherapy for the benefit of each BTC patient." 

The new metric involves quantifying the levels of two inflammatory proteins, interleukin-6 (IL-6) and YKL-40 during the patient’s journey from the initial diagnosis to the initiation of chemotherapy and beyond. Despite being incredibly rare, the researchers managed to obtain over 1500 blood samples from 452 patients diagnosed with advanced BTC. A study of this magnitude is unprecedented in the field and may prove to be transformative in improving BTC patient outcomes in the long run.

The team also uncovered another utility for targeting IL-6 beyond the scope of a diagnostic. In mouse models of BTC, blocking the cellular signaling pathways controlled by IL-6 dramatically improved the reduction in tumor size following chemotherapy.

 

Source: MedicalXpress, Clinical Cancer Research.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUL 29, 2021
Clinical & Molecular DX
Sewage Sleuths: Tracking COVID Variants in Wastewater
JUL 29, 2021
Sewage Sleuths: Tracking COVID Variants in Wastewater
Since the dawn of the pandemic, one of the biggest challenges has been monitoring the crowned enemy as it spread through ...
JUL 29, 2021
Genetics & Genomics
Obesity May Not Always Lead to Disease
JUL 29, 2021
Obesity May Not Always Lead to Disease
Some gene variants might be protecting people from the negative health effects of obesity.
AUG 04, 2021
Genetics & Genomics
Variants May Predict Which Young People Are at Risk for Severe COVID-19
AUG 04, 2021
Variants May Predict Which Young People Are at Risk for Severe COVID-19
While people carry mostly the same genes, there are many small changes in the sequences of those genes, and small variat ...
OCT 04, 2021
Cancer
Good News for Coffee Lovers: A New Study Finds Caffeine Does Not Impact Breast Cancer Risk
OCT 04, 2021
Good News for Coffee Lovers: A New Study Finds Caffeine Does Not Impact Breast Cancer Risk
Reports indicate that caffeine consumption in the United States is greatest in adults aged 50 – 64.  Coincide ...
OCT 09, 2021
Health & Medicine
Akathisia Awareness: A Closer Look
OCT 09, 2021
Akathisia Awareness: A Closer Look
Content warning: this article talks in-depth about suicide and self-harm. September was Suicide Prevention Month, but ju ...
NOV 02, 2021
Clinical & Molecular DX
No More Antibodies: COVID Test Uses Glowing Nanotubes
NOV 02, 2021
No More Antibodies: COVID Test Uses Glowing Nanotubes
Forget expensive antibody-based COVID diagnostics and long waits for test results. An innovative new approach developed ...
Loading Comments...